-
Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.
Wright D, Dragan I, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:194-200. pdf -
Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016;6:e011801. pdf -
Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:72-9. pdf -
Maternal serum PAPP-A and free beta-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:762-7. pdf -
Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia.
Wright D, Krajewska K, Bogdanova A, Wright A, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:755-61. pdf -
Mean arterial pressure at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tayyar A, Krithinakis K, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:573-9. pdf -
Uterine artery pulsatility index at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
O'Gorman N, Tampakoudis G, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:565-72. pdf -
Contingent screening for preterm pre-eclampsia.
Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:554-9. pdf -
Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis.
Roberge S, Demers S, Nicolaides KH, Bureau M, Côté S, Bujold E.
Ultrasound Obstet Gynecol 2016;47:548-53. pdf -
Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Mendez O, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:478-83. pdf -
Maternal serum placental growth factor at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Cazacu R, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:472-7. pdf -
Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Bredaki FE, Mataliotakis M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:466-71. pdf -
Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
Khalil A, Maiz N, Garcia-Mandujano R, Penco JM, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:324-31. pdf -
Uterine artery pulsatility index at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:308-15. pdf -
Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:203-9. pdf -
Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:194-202. pdf -
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, Pastides A, Shehata H.
N Engl J Med 2016;374:434-43. pdf -
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf -
First trimester prediction of HELLP syndrome.
Oliveira N, Poon LC, Nicolaides KH, Baschat AA.
Prenat Diagn 2016;36:29-33. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH.
Am J Obstet Gynecol 2016;215:87.e1-87.e17. pdf